glp-1 and metabolism Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management Glucagon-like peptide (GLP)-1 regulation of

With Defy Medical, you access: Expert Care Our experienced care team treats patients using the latest advancements in weight loss and weight management

Food Agric Immunol

S., Pronyaeva, V

These include: Nausea, vomiting, and diarrhoea (very common, especially during dose escalation) Reduced appetite and abdominal discomfort Constipation Risk of hypoglycaemia when used with insulin or sulphonylureas Pancreatitis and gallbladder disease have been reported Thyroid C-cell tumours have been observed in animal studies, though the relevance to humans is unknown Important safety considerations when using both treatments include: Mounjaro can reduce the effectiveness of oral contraceptives due to delayed gastric emptying

Lancet 2009;373:473481